Skip to main content

Changes in neurotransmitters in multiple sclerosis


Patients with multiple sclerosis were found to have increased cerebrospinal fluid, noradrenaline, and excitatory amino acid (glutamate and aspartate) levels, with increased blood glutamine, asparagine, and glycine levels. An association was found between these biochemical parameters and the nature and severity of neurological symptoms, as well as with the course of the disease. Neurotransmitters are proposed to have a role in the pathogenesis of multiple sclerosis, particularly in the biochemical mechanisms of the relationship between the nervous and immune systems, as well as in the neurochemical mechanisms underlying the development of neurological deficit.

This is a preview of subscription content, access via your institution.


  1. 1.

    É. G. Larskii, V. P. Barkhatova, and E. G. Demin. Lab. Delo,9, 519–522 (1985).

    PubMed  Google Scholar 

  2. 2.

    D. L. Bellinger, D. Lorton, and S. Y. Felten, Int. J. Immunopharmacol.,14, No. 3, 329–344 (1992).

    PubMed  CAS  Article  Google Scholar 

  3. 3.

    E. Chelmicka-Schorr and B. G. Arnason, Ann. Neurol.,36, Suppl., 29–32 (1994).

    Article  Google Scholar 

  4. 4.

    A. Compston, Ann. Neurol.,36, Suppl., 146–150 (1994).

    Article  Google Scholar 

  5. 5.

    R. A. Davidoff, in: The Origin and Treatment of Spasticity, R. Benecke, M. Emre, and R. Davidoff (eds.), USA (1990), pp. 63–91.

  6. 6.

    C. D. Dijkstra, E. R. van der Voort, C. J. de Groot, et al., Psychoneuroendocrinology,19, No. 2, 135–142 (1994).

    PubMed  CAS  Article  Google Scholar 

  7. 7.

    V. Gallai, P. Sarchielli, C. Firenze, et al., Acta Neurologica Belgica,94, No. 1, 44–52 (1994).

    PubMed  CAS  Google Scholar 

  8. 8.

    J. Jackson, R. Cross, and R. Walker, Immunology,54, 505–512 (1985).

    PubMed  CAS  Google Scholar 

  9. 9.

    J. W. Karaszewski, A. T. Reder, D. Anlar, et al., Ann. Neurol.,30, 42–47 (1991).

    PubMed  CAS  Article  Google Scholar 

  10. 10.

    J. W. Karaszewski, A. T. Reder, D. Anlar, and G. W. Arnason, J. Neuroimmunol.,43, No. 1-2, 1–7 (1993).

    PubMed  CAS  Article  Google Scholar 

  11. 11.

    F. Lechin, D. van der Dijs, A. Lechin, et al., J. Med.,25, No. 3-4, 181–192 (1994).

    PubMed  CAS  Google Scholar 

  12. 12.

    S. Lipton and R. Rosenberg, New England J. Med.,330, 613–622 (1994).

    CAS  Article  Google Scholar 

  13. 13.

    W. H. Oertel, in: Spasticity: The Current Status of Research and Treatment, M. Emre and R. Benecke (eds.), USA (1989), pp. 27–44.

  14. 14.

    J. W. Prineas and F. Connell, Curr. Neurol.,28, 68–75 (1979).

    Google Scholar 

  15. 15.

    J. S. Wolinsky, Curr. Neurol.,13, 167–207 (1993).

    Google Scholar 

Download references


Additional information

Institute of Neurology, Russian Academy of Medical Sciences, Moscow. Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 97, No. 5, pp. 7–10, May, 1997.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barkhatova, V.P., Zavalishin, I.A., Askarova, L.S. et al. Changes in neurotransmitters in multiple sclerosis. Neurosci Behav Physiol 28, 341–344 (1998).

Download citation


  • Multiple Sclerosis
  • Multiple Sclerosis Patient
  • Terbutaline
  • Excitatory Amino Acid
  • Acute Disseminate Encephalomyelitis